S.Africa in $208 mln AIDS drug venture with Swiss Lonza

February 10, 2012

South Africa on Friday unveiled plans for a 1.6 billion rand ($208 million, 157 million euro) pharmaceutical plant, in a joint venture with Swiss biochemicals group Lonza to produce anti-AIDS drugs.

The plant will produce the key ingredients needed to make the anti-retroviral drugs that have turned AIDS into a , rather than a in a nation where 5.6 million people have HIV.

"This joint venture, named Ketlaphela, will establish the first pharmaceutical plant to manufacture for anti-retroviral medicines in South Africa," Science Minister Naledi Pandor told journalists.

South Africa will invest 1.1 billion rands, while Lonza will put 500 million rands into the plant, whose name means "I will survive" in Sotho, she said.

"Lonza's high Swiss standards plus their superb track record of establishing and maintaining successful commercial operations in developing countries, make them a valuable and desirable partner," Pandor said.

The new plant will help stabilise the price of drugs used to fight AIDS, as South Africa currently imports the main ingredients needed.

The plant will create about 2,600 jobs once it's running in 2016, he added. About 3,800 people will be employed for its construction.

South Africa has the world's largest programme, serving 1.3 million people.

The treatment programme has already made gains in combating the epidemic, but the numbers of people needing drugs will keep growing as more and more people begin a lifetime on the medicines.

Explore further: South Africa unveils plan to halve HIV infections

Related Stories

South Africa unveils plan to halve HIV infections

December 1, 2011

President Jacob Zuma on Thursday unveiled a plan to halve the number of HIV infections over the next five years, cementing South Africa's turnaround from years of deadly denialism.

Recommended for you

Researchers use CRISPR to accelerate search for HIV cure

October 25, 2016

Researchers at UC San Francisco and the academically affiliated Gladstone Institutes have used a newly developed gene-editing system to find gene mutations that make human immune cells resistant to HIV infection.

Study unlocks secret of common HIV strain

October 13, 2016

A discovery that the most common variant of the HIV virus is also the "wimpiest" will help doctors better treat millions of individuals around the world suffering from the deadly disease, according to one of the world's leading ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.